# US 12,605,391 B2 · Methods of treating testosterone deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,605,391 B2
- Document ID: US12605391B2
- Status: Granted
- Kind: B2
- Application number: 18/086,994
- Filed: 2022-12-22
- Published: 2023-07-13
- Granted: 2026-04-21
- Earliest claimed: 2019-04-12
- Assignees: Tolmar, Inc.
- Applicants: Tolmar, Inc.
- Inventors: Robert E. Dudley; Theodore Danoff; James A. Longstreth
- Web page: https://patentgrep.com/patent/US12605391B2

## CPC

- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4858: {Organic compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. In some embodiments, the subject has adequately controlled blood pressure.

## Claims

### Claim 1

A method of treating one or more conditions associated with a deficiency or absence of endogenous testosterone in a subject, comprising:
administering a defined dose of testosterone undecanoate to the subject in an oral pharmaceutical composition twice daily, once in the morning and once in the evening, wherein the defined dose is selected from 158 mg, 198 mg, 237 mg, 316 mg, and 396 mg of testosterone undecanoate; and
monitoring the subject's blood pressure after administration of the defined dose;
wherein:
the subject has adequately controlled blood pressure-at the time the oral pharmaceutical composition is first administered; and
the oral pharmaceutical composition comprises the testosterone undecanoate solubilized in a carrier comprising at least one hydrophilic surfactant and at least one lipophilic surfactant.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is not being treated with antihypertensive therapy.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is being treated with antihypertensive therapy.

### Claim 4 (depends on 1)

The method of claim 1, further comprising treating the subject for new-onset hypertension or exacerbation of pre-existing hypertension.

### Claim 5 (depends on 1)

The method of claim 1, further comprising, prior to administration of the pharmaceutical composition, informing the subject that administration of the pharmaceutical composition may result in an increase in blood pressure.

### Claim 6 (depends on 1)

The method of claim 1, wherein administration of the oral pharmaceutical composition results in an average increase of systolic blood pressure of 4.9 mm Hg based on ambulatory blood pressure monitoring.

### Claim 7 (depends on 1)

The method of claim 1, further comprising, prior to administration of the pharmaceutical composition, informing the subject that co-administration of the oral pharmaceutical composition with a prescription medication known to increase blood pressure and/or a nonprescription analgesic and/or a cold medication may result in additional increases in blood pressure.

### Claim 8 (depends on 1)

The method of claim 1, further comprising monitoring the subject for new-onset hypertension or exacerbation of pre-existing hypertension.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject has one or more cardiovascular risk factors or established cardiovascular disease.

### Claim 10 (depends on 1)

The method of claim 1, wherein the defined dose is 237 mg.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject is diagnosed with primary hypogonadism.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is diagnosed with hypogonadotropic hypogonadism.

### Claim 13 (depends on 1)

The method of claim 1, wherein the lipophilic surfactant is a fatty acid.

### Claim 14 (depends on 1)

The method of claim 1, wherein the hydrophilic surfactant is a hydrogenated castor oil ethoxylate.

### Claim 15 (depends on 1)

The method of claim 1, wherein the oral pharmaceutical composition further comprises a digestible oil.

### Claim 16 (depends on 1)

The method of claim 1, wherein the oral pharmaceutical composition comprises about 18-22% (w/w) testosterone undecanoate.

### Claim 17 (depends on 1)

The method of claim 1, wherein the ratio (w/w) in the composition of total lipophilic surfactant to total hydrophilic surfactant is in the range of about 6:1 to about 3.5:1.

### Claim 18 (depends on 1)

The method of claim 1, wherein the lipophilic surfactant is oleic acid and the hydrophilic surfactant is a hydrogenated castor oil ethoxylate.
